EY Life Sciences 4.0 podcast series by EY

In this episode of the EY Health Sciences and Wellness Experience Podcast, Aloha McBride and her guests explore how organizations can reduce climate impact, increase efficiencies and unburden the system.

The speakers talk about the EY report Pharma supply chains of the future and discuss the impact of global events and how a new supply chain model can emerge. Until recently, the pharma industry has been on the straight path to globalization with integrated supply chains that crossed national borders. A series of geopolitical upheavals though, from the COVID-19 pandemic, to the crisis in Ukraine, caused the industry to re-examine its priorities. The COVID-19 pandemic and global political tensions highlighted the downsides of a highly integrated supply chain with global dependencies. Politicians started seeking greater guarantees of national and regional supply, rebalancing supply chains to national security and interests. The discussion then moves to the response of the pharma industry in incorporating regionalization. A hybrid model is emerging that combines globalized thinking with greater self-sufficiency. The key is end-to-end visibility so that companies have a clear line of sight of their supply chain, enabling manufacturing to continue, even in the face of short-term crises, geopolitical tensions, or cyberattacks. Two positives that emerged from the COVID-19 pandemic were greater collaboration between pharma companies, demonstrated by the vaccine development, and greater dialogue with policy makers. The way forward is the development of a partnership between pharma companies, policy makers, and regulatory bodies to build a new, resilient supply chain model. Key takeaways: Global tensions and crises have put pressure on pharma companies to re-examine their supply chains. The emerging model is a hybrid one that combines globalization with regionalization. End-to-end visibility is essential, not just with suppliers but with suppliers of suppliers. The supply chain of the future will involve public/private partnerships and greater collaboration between stakeholders. For your convenience, full text transcript of this podcast is also available. Read the transcript. 

In this episode, Barend van Bergen, EY Global Long-term Value Methodology Leader and Sonja Haut, Head of Impact Valuation for Novartis discuss how companies are measuring their ESG impact.

In this episode of the EY Health Sciences and Wellness Experience podcast, Pamela Spence, EY Global Health Sciences and Wellness Leader, talks with Nancy Flores, Executive Vice President & Chief Information and Technology Officer for McKesson Corporation, about the unique complexities of healthcare – a sector with new entrants, new regulations, consolidation, pricing pressures, and an ageing population that needs ever more healthcare. But alongside the complexities, there are opportunities to disrupt.

In this episode of the EY Health Sciences and Wellness Experience podcast, Pamela Spence, EY Global Health Sciences and Wellness Leader, speaks with Trecilla Lobo, SVP, People, BenevolentAI, Rabia Khan, Founder/CEO, Ladder Therapeutics, and Samin Saeed, UK Chief Scientific Officer and Medical Director, Novartis, as they discuss their own unique career journeys within the health sciences and wellness industry. They also share with us those critical lessons they have learned from their mentors and supporters along the way.

In this episode of the EY Health Sciences and Wellness Experience Podcast, Pamela Spence, EY Global Health Sciences and Wellness Leader, Jackie Hunter, Board Director of Benevolent AI and Ridwaan Jhetam, VP Global Medical for Hematology, BMS, discuss the important of data and how it can help redesign the health experience. In this wide-ranging discussion, the expert panel approach these issues from their different perspectives. Whether you're a doctor or researcher, a programmer or a CIO, whether you work in the field or you're just looking in from outside, you'll find this an insightful and timely listen.

There are 2,600 cell and gene therapy clinical trials taking place this year. In the US alone, this could translate up to 20 new therapy approvals in 2022, which presents a clear opportunity to make more life-saving therapies available to a greater number of individuals. In this podcast, Adlai Goldberg, Global Digital, Social and Commercial Innovation Life Sciences Leader for EY, talks to Tamie Joeckel – ICON's Cell and Gene Therapy Global Business Lead, as they discuss what makes an increase in the volume of trials and an acceleration of the clinical trial process significant.

In this Pointellis episode, Adlai Goldberg and two prominent chief medical officers explore and frame the health equity challenges the world is facing today. Addressing health care inequality is a global challenge. For Dr. Yele Aluko, EY Chief Medical Officer, and Dr. David Rhew, Microsoft Chief Medical Officer, finding opportunities to provide health equity is a shared passion. Both are experienced physicians, and in this podcast, we discuss why disparities exist, the root causes and unbiased digital solutions. Health care disparity doesn't begin at the time of diagnosis and treatment – it goes back further to clinical trials and the fact that low enrolment rates of minorities would generate results that were not reflective of the populations. And while COVID-19 has both given rise to a groundswell of societal demand for equal treatment for all people, the pandemic has also highlighted the health disparities across populations. The way forward requires strategic insight from the health care value chain. Using data and analytics to not only identify care gaps – but to then develop the tactics and solutions that will close them. Microsoft is building technologies that can be used by millions to make things easier, with usability a key factor. Barriers such as lack of broadband, or physical disabilities such as poor vision and hearing, must be overcome. Dr. Aluko and Dr. Rhew see health equity is an important mission, because achieving it means everyone has a better chance of fulfilling their life's potential.

In this first episode of our EY Health Sciences and Wellness Experience podcast series, we explore the emerging and much needed age of “Health Experience.” The Health Sciences and Wellness industry has never been as “front and center” in our lives as it has been in this last year. As all of us, worldwide, ride the various waves of the pandemic, our Health Sciences and Wellness industry has taken the lead in giving care to those who have needed it most. We have also seen a monumental collaborative R&D effort – at a scale never witnessed before – which has resulted in the creation and delivery of multiple approved vaccines to combat the virus. Companies have an opportunity to seize this inflexion point, because the reality (as we have seen with other industries) is that products or services alone, no matter how strong technically will not be enough in future.  

The COVID-19 pandemic provides the ‘burning platform’ for accelerating the data agenda. New data-based tools and technologies make a more personalized approach to health and wellness possible. The world has never needed this more than now. While companies and organizations long recognized the potential of new tools to capture and use data to transform health, they lacked the “burning platform” to fuel this change. The COVID-19 pandemic and the global disruption it caused has demonstrated that organizations can become more resilient, agile and innovative if they shift to digitally enabled business models with data at the core.

New technologies are creating new opportunities, but they are also creating unknown and unquantified risks. Organizations that understand what it takes to succeed with new cost and revenue models, new value propositions, and new relationships with the right partners, will start to reshape the health market. In this edition of New Horizons, we explore four areas where this process of reshaping is underway.

With dealmaking a cornerstone of the growth strategy, 2020 will be a robust year for life sciences M&A. To succeed, companies must continue to focus their business models, close near term growth gaps and invest in future innovation.

In the EY 2019 Pulse of the industry, we review the performance of the global medical technology industry. The industry continues to grow, but its long-term outlook is at risk from underinvestment in R&D and lack of collaboration between industry providers, payers and patients.

Nothing can change if minds do not. How can we make common ground the foundation for real change? As technology increasingly takes on the role of management, more emphasis falls on the role of leaders. Neuroscience is uncovering approaches to influence that leaders can use to enlist others to share their beliefs and commitments.   In this episode of The Better Question, EYQ Fellow Chris Meyer is joined by Tali Sharot, professor of cognitive neuroscience at University College London and EYQ Fellow, and Seth Godin, entrepreneur and author of numerous bestsellers, including Permission Marketing: Turning Strangers into Friends and Friends into Customers.

Data is the driving force underpinning the Fourth Industrial Revolution and the emergence of new business models. In health care, the goal is to use data to deliver interventions more proactively and in more personalized ways, ultimately leading to better health outcomes and a shift to prevention. Five trends are leading the rise of a new, data-centric approach to health care. An organization’s ability to generate value depends on how effectively it can unlock the power of data and generate insights by connecting, combining and securely sharing data at greater scale than ever before. Learn more by visiting us at ey.com/lifesciences Additional audiobook formats include iTunes | Google Play Music | Spotify

Over the past three decades, life sciences companies have used their biological and chemical know-how to create significant value for themselves, their shareholders and most importantly patients. In today’s fast-changing environment, it’s very likely that life sciences companies will need access to an array of medical and non-medical data to demonstrate value to their stakeholders. In the latest 2019 EY M&A Firepower report, we explore the dealmaking strategies life sciences should prioritize to generate growth. This year’s findings show that life sciences companies must accelerate their agendas on the creation of focused business models and the acquisition of disruptive, digital capabilities. Learn more by visiting us at ey.com/firepower Additional audiobook formats include ​iTunes | Google Play Music | Spotify​

An EY study shows that data and digital are transforming the life sciences industry. Hear from leaders how industry players can seize the upside of this disruption, and what it means for patient-consumers.

In EY Pulse of the industry, we examine the annual performance of the medical device industry in the context of the technological advances and rising customer expectations associated with the Fourth Industrial Revolution. To thrive in this transformative age, medtechs must adapt their business models to meet the increased expectations of consumers and other health stakeholders. Read more by visiting www.ey.com/pulse Additional audiobook formats include iTunes | Google Play Music | ​Spotify

In Life Sciences 4.0: securing value through data-driven platforms, we explore how health is being reimagined because of scientific and technological change and rising customer expectations. We also examine the ramifications for life sciences companies' market offerings, business models and the new capabilities needed as the disciplines of health care and technology merge to become "health technology". Read more by visiting us at ey.com/lifesciences  Additional audiobook formats include iTunes | Google Play Music | ​Spotify